2022年11月15日

2022年的11月15日,Kevin Eisenfrats Contraline,维吉尼亚州生物技术公司开发一种长效避孕对于男人来说,串联已经筹集了720万美元资金从投资者由谷歌的风险的手臂问。其他投资者包括纽约MBX资本,加州公司石墨烯项目,Rhia Ventures ShangBay资本和安波易街项目,爱沙尼亚的Metaplanet控股。在弗吉尼亚州的夏洛茨维尔,公司目前已经筹集了2460万美元,包括1070万美元的系列MBX资本,领导的2021年和800000美元的赠款非营利弗吉尼亚催化剂。希望寄托在“亚当”Contraline正在测试一种可注射水凝胶,被称为亚当,在澳大利亚。无激素和非永久性植入目标的一部分男性解剖学叫输精管,传输成熟精子的尿道,使射精和怀孕。亚当的目的是阻止精子流预定义的一段时间。“我们已经完成了临床前研发和制造亚当系统用于人类,和我们现在有融资、伦理批准,和团队以亚当过渡到临床试验,“Contraline联合创始人兼首席执行官凯文Eisenfrats去年说经过前一轮融资。“这审判将推出新一代的无激素的男性避孕药,增加选择男性和实现公共卫生影响。“年轻的领导人正在进行的试验中,四人被植入了亚当在墨尔本的积分共济会医院采用微创手术局部麻醉的情况下在门诊。试验是由首席研究员Nathan Lawrentschuk,皇家墨尔本医院的泌尿学教授和积分医院,和研究员保罗·安德森。 A larger trial is planned in the United States later. In 2017, Eisenfrats was named in Forbes’ “30 Under 30” in healthcare. He holds 36 patents for varied work in novel contraceptive drugs and devices, biomaterials, drug delivery, and surgical devices. Bulk of his research has been in immunotherapy, reproductive biology and in vitro fertilization. He has a degree in Nanomedicine Engineering and Chemistry from the University of Virginia. Investors Virginia Catalyst, which handed out grants to Contraline, is a not-for-profit corporation created by the Virginia General Assembly and funded by the Commonwealth’s General Fund and seven Virginia public research universities. Michael Grisham, founder of GPB Scientific, serves as its president and CEO. He has over two decades’ experience in biosciences, and has founded and led Celective DX (acquired by On-Q-ity); Verinata Health (acquired by Illumina), and Paradigm Health Corporation (acquired by Alere). citybiz+ Sponsors New York-headquartered MBX has over $75 million in assets under management. It has made 39 portfolio investments and completed two exits. Its cofounder, Gurdane Bhutani, believes Adam “has the potential to be a first-of-its-kind product that revolutionizes how we think about contraception.” GV, known initially as Google Ventures, was established in 2009. Google’s parent company, Alphabet, is its sole limited partner. Cathy Friedman, an industry veteran with nearly 40 years’ experience, serves as its executive venture partner. She established Morgan Stanley’s biotech practice on the West Coast and has over a decade’s experience of serving on the boards of life sciences startups. Friedman oversees GV’s investments in life sciences and healthcare firms.